Kennedy Capital Management, Inc. Design Therapeutics, Inc. Transaction History
Kennedy Capital Management, Inc.
- $4.23 Billion
- Q4 2024
A detailed history of Kennedy Capital Management, Inc. transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Kennedy Capital Management, Inc. holds 14,266 shares of DSGN stock, worth $70,331. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,266Holding current value
$70,331% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding DSGN
# of Institutions
97Shares Held
32.1MCall Options Held
4.6KPut Options Held
2.6K-
Sr One Capital Management, LP6.53MShares$32.2 Million14.99% of portfolio
-
Logos Global Management LP San Francisco, CA4.22MShares$20.8 Million3.42% of portfolio
-
Black Rock Inc. New York, NY2.3MShares$11.4 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.95MShares$9.63 Million0.72% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.86MShares$9.15 Million0.03% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $275M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...